Compare SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SP Funds S&P 500 Sharia Industry Exclusions ETF vs TG Therapeutics Inc — how do they compare? SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59.07, while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SPUS | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $59.51 | $59.06 |
52-Week Low | $46.28 | $26.94 |
Market Cap | — | $7.64B |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPUS trades at $59.11, up 0.27% today, with technical indicators showing a bullish trend supported by moving averages. The stock exhibits strong momentum with key indicators favoring upside potential. Recent dividend distributions of $0.03 per share in H1-26 demonstrate shareholder returns, though key valuation metrics remain undisclosed in current data.
The outlook remains positive given technical strength and dividend consistency, though limited fundamental data availability warrants caution. Key risks include market volatility and potential overbought conditions indicated by short-term RSI levels. Investors should monitor upcoming earnings for fundamental validation of current technical optimism.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
